Introduction {#S1}
============

Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) are heterodimeric glycoprotein hormones, acting on the same receptor (LHCGR) ([@B1]). These gonadotropins were considered equivalent at the molecular level for long time, until the demonstration of specific intracellular-mediated signaling ([@B2]). *In vitro* models of human granulosa cells demonstrated that hCG is more potent than LH in inducing cyclic adenosine monophosphate production (cAMP) production ([@B2]), while the latter leads to preferential ERK1/2 and AKT pathways activation ([@B2]). Thus, although LH and hCG activate different kinetics ([@B2], [@B3]), whether and how they differently influence *in vivo* response remains unclear ([@B4]).

In humans, follicle-stimulating hormone (FSH) and LH act in concert to stimulate folliculogenesis and ovulation. Therefore, these gonadotropins are used in the controlled ovarian stimulation (COS) in order to produce relatively high oocyte number to be used fresh or after cryopreservation ([@B5]) to obtain pregnancies. The physician identifies the presumably most appropriate regimen, in terms of gonadotropin-releasing hormone (GnRH) analog protocol, FSH formulation, starting FSH dose, and combination of different gonadotropins, following the evaluation of demographic, anthropometric, and ovarian reserve profiles ([@B6]--[@B8]). Generally, FSH is selected as standard treatment, and hCG or LH may be added. The knowledge of human physiology provides a rationale for LH activity supplementation during COS. Although *in vitro* and animal models provided the evidences of hormone-specific actions, the choice of the optimal gonadotropin combination to be used in COS is not well standardized and remains entrusted to clinician's decision. Especially, the pregnancy hormone hCG is generally used to obtain LH-like activity and support of multi-follicle growth since decades ([@B9]). With this in mind, human menopausal gonadotropin (hMG) is commonly used as preparation with LH-like activity, due to the presence of LH and/or hCG molecules. hMG alone and hCG/LH + FSH were repeatedly proposed ([@B10], [@B11]) but some unfavorable results, in particular in terms of number of oocytes retrieved ([@B12], [@B13]), provided concerns about the usefulness of addition of "LH activity."

Currently, the gonadotropin market offers a wide choice, including urinary and recombinant preparations of FSH, LH, hCG, and hMG alone or in various combinations, recently further enriched by biosimilars. This palette of competitor drugs, registered for the same indication but biochemically and physiologically different, introduced the concept of "personalized" assisted reproductive technology (ART) schemes, which is very attractive for patients and doctors but not supported by solid evidence and largely industry-promoted. These gonadotropins show different kinetics in *in vitro* models, but no clear *in vivo* differences in COS are available so far. Most studies have been tried to answer the question of what is the best gonadotropin combinations, although inconclusive results were achieved, not sufficient to guide a really evidence-based, personalized choice in ART. Indeed, no powerful, properly designed, controlled prospective clinical trials are available to support the rationale of any COS scheme so far. As a matter of fact, the design of randomized clinical trials is challenging in this setting, due to the peculiar emotional situation and heterogeneity of the infertile population together with the time and costs required. Thus, 64 meta-analyses have been published to compare different ART approaches and outcomes (Table [1](#T1){ref-type="table"}). However, each review is focused on a specific single comparison (e.g., hMG vs. FSH, GnRH agonist vs. antagonists, etc.) in a peculiar clinical setting. In particular, 25 systematic reviews compared the efficacy of different GnRH analogs, 17 compared urinary and recombinant FSH preparations, and only 6 evaluated the efficacy of LH supplementation to FSH (Table [1](#T1){ref-type="table"}). None of these comparisons provided a comprehensive analysis of entire process, from oocyte recruitment to live birth rate, and their conclusions are rarely translated in clinical practice. In fact, no accepted guideline exists in this field of medicine in which registered indications and reimbursability of gonadotropins by the national health care systems are guided by costs rather than scientific evidence/clinical outcome.

###### 

**Previous meta-analysis characteristics**.

  First author      Journal                      Year   Comparison                                                                   End-points               Number of studies
  ----------------- ---------------------------- ------ ---------------------------------------------------------------------------- ------------------------ -------------------
  Daya              Fertil Steril                1995   U-follicle-stimulating hormone (FSH) vs. r-FSH                               Pregnancy rate           8
  Daya              Cochrane Database Syst Rev   1996   U-FSH vs. r-FSH                                                                                       Withdrawan
  Daya              Hum Reprod                   1999   U-FSH vs. r-FSH                                                              Oocytes retrieved        12
  Nugent            Cochrane Database Syst Rev   2000   Different u-FSH in polycystic ovarian syndrome (PCOS)                        Pregnancy rate           23
  Daya              Cochrane Database Syst Rev   2000   U-FSH vs. r-FSH                                                              Pregnancy rate           18
  van Wely          Fertil Steril                2003   Human menopausal gonadotropin (hMG) vs. r-FSH                                Pregnancy rate           6
  Al-Inany          Hum Reprod                   2003   U-FSH vs. r-FSH                                                              Oocytes retrieved        20
  Albuquerque       Cochrane Database Syst Rev   2005   Depot gonadotropin-releasing hormone (GnRH) agonist vs. daily GnRH agonist   Pregnancy rate           6
  Pandian           Cochrane Database Syst Rev   2005   *In vitro* fertilization (IVF) vs. intrauterine insemination (IUI)           Pregnancy rate           10
  Sallam            Cochrane Database Syst Rev   2006   GnRH agonist timing in endometriosis                                         Pregnancy rate           3
  Griesinger        Reprod Biomed Online         2006   GnRH agonist vs. GnRH antagonist in PCOS                                     Oocytes retrieved        13
  Franco            Reprod Biomed Online         2006   GnRH agonist vs. GnRH antagonist in PCOS                                     Oocytes retrieved        6
  Sunkara           Reprod Biomed Online         2007   GnRH agonist vs. GnRH antagonist                                             Oocytes retrieved        9
  Mochtar           Cochrane Database Syst Rev   2007   R-luteinizing hormone (LH) plus r-FSH vs. r-FSH                              Live birth rate          14
  Pandian           Cochrane Database Syst Rev   2007   Different GnRH analog protocols                                              Live birth rate          9
  Daya              Cochrane Database Syst Rev   2007   U-FSH vs. r-FSH                                                                                       Withdrawan
  Kolibianakis      Hum Reprod Update            2007   R-LH plus r-FSH vs. r-FSH in GnRH antagonist                                 Live birth rate          5
  Baruffi           Reprod Biomed Online         2007   R-LH plus r-FSH vs. r-FSH in GnRH antagonist                                 Oocytes retrieved        5
  Al-Inany          Reprod Biomed Online         2008   hMG vs. r-FSH                                                                Live birth rate          10
  Coomarasamy       Hum Reprod                   2008   U-FSH vs. r-FSH                                                              Live birth rate          7
  Al-Inany          Reprod Biomed Online         2008   hMG vs. r-FSH                                                                Live birth rate          5
  Al-Inany          Gynecol Endocinol            2009   hMG vs. r-FSH                                                                Pregnancy rate           6
  Jee               Gynecol Obstet Invest        2010   hMG vs. r-FSH                                                                Pregnancy rate           10
  Lehert            Reprod Biol Endocrinol       2010   hMG vs. r-FSH                                                                Oocytes retrieved        16
  Pandian           Cochrane Database Syst Rev   2010   GnRH agonist vs. GnRH antagonist                                             Live birth rate          15
  Pandian           Cochrane Database Syst Rev   2010   Different GnRH analog protocols                                              Live birth rate          10
  Sterrenburg       Hum Reprod Update            2011   Different r-FSH doses                                                        Pregnancy rate           10
  Al-Inany          Cochrane Database Syst Rev   2011   GnRH agonist vs. GnRH antagonist                                             Live birth rate          45
  Youssef           Cochrane Database Syst Rev   2011   GnRH agonist vs. hCG for trigger                                             Live birth rate          11
  van Wely          Cochrane Database Syst Rev   2011   hMG vs. r-FSH                                                                Live birth rate          42
  Youssef           Cochrane Database Syst Rev   2011   U-hCG vs. r-hCG                                                              Live birth rate          14
  Siristatidis      Cochrane Database Syst Rev   2011   Different GnRH agonist protocols                                             Pregnancy rate           29
  Maheshwari        Cochrane Database Syst Rev   2011   Short vs. ultra-short GnRH agonist protocols                                 Pregnancy rate           29
  Pundir            Hum Reprod                   2011   GnRH agonist vs. GnRH antagonist                                             Oocytes retrieved        14
  Bodri             Fertil Steril                2011   GnRH agonist vs. GnRH antagonist                                             Pregnancy rate           8
  van Wely          Hum Reprod Update            2012   hMG vs. r-FSH                                                                Live birth rate          42
  Hill              Fertil Steril                2012   R-LH plus r-FSH vs. r-FSH in GnRH antagonist                                 Pregnancy rate           7
  Konig             Fertil Steril                2012   R-LH plus r-FSH vs. r-FSH in GnRH antagonist in women older than 35 years    Pregnancy rate           9
  Mahmoud Youssef   Fertil Steril                2012   Long acting FSH vs. r-FSH                                                    Pregnancy rate           4
  Pandian           Cochrane Database Syst Rev   2012   IVF vs. IUI                                                                  Pregnancy rate           6
  Gibreel           Cochrane Database Syst Rev   2012   Gonadotropins vs. clomiphene citrate                                         Live birth rate          14
  Pouwer            Cochrane Database Syst Rev   2012   Long acting FSH vs. r-FSH                                                    Live birth rate          4
  Pundir            Reprod Biomed Online         2012   GnRH agonist vs. GnRH antagonist in PCOS                                     OHSS rate                9
  Albuquerque       Cochrane Database Syst Rev   2013   Depot GnRH agonist vs. daily GnRH agonist                                    Pregnancy rate           16
  Matsaseng         Gynecol Obstet Invest        2013   Mild ovarian stimulations vs. traditional IVF                                Pregnancy rate           5
  Xiao              Fertil Steril                2013   GnRH agonist vs. GnRH antagonist                                             Pregnancy rate           12
  Fan               Gynecol Endocinol            2013   rLH supplementation in poor responders                                       Pregnancy rate           3
  Xiao              Gynecol Endocinol            2013   GnRH agonist vs. GnRH antagonist                                             Oocytes retrieved        7
  Youssef           Cochrane Database Syst Rev   2014   GnRH agonist vs. hCG for trigger                                             Live birth rate          17
  Xiao              PlosONE                      2014   GnRH agonist vs. GnRH antagonist                                             Oocytes retrieved        23
  Chen              Gynecol Endocinol            2014   Timing of hCG administration                                                 Oocytes retrieved        7
  Lin               PlosONE                      2014   GnRH agonist vs. GnRH antagonist                                             Pregnancy rate           9
  Hu                J Int Med Res                2014   LH priming vs. FSH alone                                                     Estradiol serum levels   3
  Song              Gynecol Endocinol            2014   GnRH agonist vs. letrozole                                                   Pregnancy rate           3
  Siristatidis      Cochrane Database Syst Rev   2015   different GnRH agonist protocols                                             Pregnancy rate           37
  Weiss             Cochrane Database Syst Rev   2015   U-FSH vs. r-FSH in PCOS                                                      Live birth rate          14
  Nugent            Cochrane Database Syst Rev   2015   Different u-FSH in PCOS                                                                               Withdrawan
  Nahuis            Cochrane Database Syst Rev   2015   U-FSH vs. r-FSH in PCOS                                                                               Withdrawan
  Pandian           Cochrane Database Syst Rev   2015   IVF vs. IUI                                                                  Pregnancy rate           8
  Pouwer            Cochrane Database Syst Rev   2015   Long acting FSH vs. r-FSH                                                    Live birth rate          6
  Youssef           J Adv Res                    2015   GnRH agonist vs. hCG for trigger                                             Pregnancy rate           19
  Fensore           J Ovar Res                   2015   Long acting FSH vs. r-FSH                                                    Oocytes retrieved        7
  Al-Inany          Cochrane Database Syst Rev   2016   GnRH agonist vs. GnRH antagonist                                             Live birth rate          63
  Youssef           Cochrane Database Syst Rev   2016   U-hCG vs. r-hCG                                                              Live birth rate          18

Having in mind physiology and the different *in vitro* effects of LH and hCG, in this work, we addressed the question whether LH, LH-like activity, and hCG could have different results on COS outcomes. To this purpose, we evaluated the efficacy of LH or hCG plus FSH or hMG alone, compared to what is considered the standard care for COS, i.e., the use of FSH alone, using a meta-analytic approach. This is the first meta-analysis in which all gonadotropin combinations are considered. Moreover, a full-spectrum evaluation of all ART endpoints is provided, to recognize when and how LH, LH-activity, and hCG influence ART outcomes.

Materials and Methods {#S2}
=====================

We performed a meta-analysis according to the Cochrane Collaboration and PRISMA statement. The meta-analysis was accepted in the International Prospective Register of Systematic Reviews (PROSPERO; registration n. CRD42016048404) prior to commencing the study, ensuring transparency and originality of the review process.

Data Sources and Searches {#S2-1}
-------------------------

We conducted a comprehensive literature search for English-language articles in MEDLINE (PubMed), EMBASE, Cochrane Library, SCOPUS, and UpToDate, published until July 2016. Search key words were as follows: controlled ovarian stimulation (COS), controlled ovarian hyperstimulation (COH), ART, *in vitro* fertilization (IVF), intracytoplasmatic sperm injection (ICSI), luteinizing hormone (LH), follicle stimulating hormone (FSH), human menopausal gonadotropin (hMG), hCG, follitropin, oocytes retrieved, and pregnancy. The Boolean functions AND and OR were used to combine key words listed above.

Study Selection and Inclusion Criteria {#S2-2}
--------------------------------------

### Types of Studies {#S2-2-1}

The inclusion criteria, established before the literature search, were Prospective, longitudinal, and controlled clinical trials;Enrollment of women without limits of age;Treatment with LH or hCG or hMG during the follicular development phase.

Retrospective studies were not included. Similarly, trials enrolling women with polycystic ovarian syndrome (PCOS) were excluded, due to peculiar endocrine features of these patients. The ART methodology chosen was not an inclusion or exclusion criterion. However, each outcome was further evaluated considering the studies on the basis of the ART protocol used. Finally, randomization was not considered a strict inclusion criterion, thus randomized, semirandomized, and non-randomized clinical trials were reviewed. Therefore, all available controlled studies were considered increasing sample size, in spite of the wide range of clinical protocols available.

### Type of Participants {#S2-2-2}

Women undergoing COS for ART were considered. No inclusion criteria were applied for the male partner of the infertile couple.

### Type of Interventions {#S2-2-3}

All ART stimulation protocols were considered and studies included provided the comparison between LH, hCG, or hMG in the follicular phase with FSH.

Data Collection Process and Quality {#S2-3}
-----------------------------------

Two authors (Santi Daniele and Casarini Livio) extracted the abstracts from all studies found through literature search until July 2016. All abstracts were evaluated for inclusion criteria, and data were extracted from each study considered eligible, with regard to study design, year of publication, number of included/excluded subjects, number of dropped-out patients, and the use of intention to treat or per protocol analysis.

The quality of trials was assessed using the parameters proposed by Jadad et al. ([@B14]) and Table [2](#T2){ref-type="table"} summarizes the features of the selected studies.

###### 

**Characteristics of included studies**.

                                                                                                             Control group                                                                 Study group                                                                     
  ----------------- ------ ----------------------------------------------- --------------------------------- --------------- ------ ----- ----------- ----- ------ ------------ ----- ---- ------------- ------ ----- ------------ --------- ----- ------------ ---------- ----
  Gerli             1993   Gonadotropin-releasing hormone (GnRH) agonist   *In vitro* fertilization (IVF)    17              30.9   FSH   Metrodin    225                             2    15            31.4   hMG   Pergonal     225                                     1
  Daya              1995   GnRH agonist                                    IVF                               115             33.5   FSH   Metrodin    150                                  117           33.2   hMG   Pergonal     150                                     
  Westergaard       1996   GnRH agonist                                    IVF                               104             31.0   FSH   Fertinorm   225                                  114           32.0   hMG   Pergonal     225                                     
  Jansen            1998   None                                            IVF                               47              32.0   FSH   Puregon     150                                  32            31.1   hMG   Humegon      225                                     
  Filicori          1999   GnRH agonist                                    IVF                               10              32.0   FSH   Metrodin    300                             0    10            33.0   FSH   Metrodin     300       hCG   Profasi      50         0
  Sills             1999   GnRH agonist                                    IVF                               17              35.4   FSH   Fertinex                                         14            36.7   FSH   Fertinex               LH    Lhadi        75         
  Balasch           2001   GnRH agonist                                    IVF                               14              33.6   FSH   Gonal F     150                             1    16            34.8   FSH   Gonal F      150       LH    Luveris      75         1
  De Placido        2001   GnRH agonist                                    IVF                               40              30.1   FSH   Gonal F     300                             0    20            31.6   FSH   Gonal F      150       hMG   Menogon      150        0
  Filicori          2001   GnRH agonist                                    IVF                               25              32.0   FSH   Metrodin    150                             0    25            33.0   hMG   Menogon      150                                     0
  Gordon            2001   GnRH agonist                                    IVF                               69              33.5   FSH   Puregon     225                             12   59            33.5   hMG   Humegon      75                                      6
  Ng                2001   GnRH agonist                                    IVF                               20              33.5   FSH   Gonal F     300                                  20            32.0   hMG   Pergonal     300                                     
  Strehler          2001   GnRH antagonist                                 IVF                               248             32.3   FSH   Gonal F     300                                  259           31.8   hMG   Menogon      300                                     
  Westergaard       2001   GnRH agonist                                    IVF                               190                    FSH   Gonal F     225                             2    189                  hMG   Menogon      225                                     3
  Filicori          2002   GnRH agonist                                    IVF                               30              31.9   FSH   Metrodin    150                                  90            32.7   FSH   Metrodin     150       LH    Menogon      75         
  Ismail            2002   GnRH agonist                                    IVF                               75              33.2   FSH   Fostimon    150                                  78            34.3   hMG   Menogon      150                                     
  Lisi              2002   GnRH agonist                                    IVF                               331             34.7   FSH   Gonal F     150                                  122           34.8   FSH   Gonal F      150       LH    Luveris      75         
  Filicori a        2003   GnRH agonist                                    Intrauterine insemination (IUI)   25              31.9   FSH   Gonal F     150                                  25            32.6   hMG   Menogon      150                                     
  Filicori b        2003   GnRH agonist                                    IVF                               50              25.9   FSH   Gonal F     150                             14   50            27     hMG   Menopur      150                                     12
  Ku                2003   GnRH agonist                                    IVF                               19              34.6   FSH   Metrodin    300                                  26            33.0   FSH   Metrodin     300       hMG   Pergonal     75         
  Marrs             2003   GnRH agonist                                    IVF                               219             31.9   FSH   Gonal F     225                                  212           32.4   FSH   Gonal F      225       LH    Luveris      150        
  Acevedo           2004   GnRH antagonist                                 IVF                               20              23.0   FSH   Gonal F     225                                  22            26.0   FSH   Gonal F      225       LH    Luveris      75         
  Cédrin-Durnerin   2004   GnRH antagonist                                 IVF                               96              31.7   FSH   Gonal F     150                             2    107           31.4   FSH   Gonal F      150       LH    Luveris      75         0
  De Placido        2004   GnRH agonist                                    IVF                               46              30.4   FSH   Gonal F     150                                  46            30.0   FSH   Gonal F      150       LH    Luveris      75         
  Ferraretti        2004   GnRH agonist                                    IVF                               104             31.7   FSH   Gonal F     225                             2    54            31.5   FSH   Gonal F      225       LH    Luveris      75         4
  Ferraretti        2004   GnRH agonist                                    IVF                               104             31.7   FSH   Gonal F     225                             2    22            32.0   FSH   Gonal F      225       hMG   Menogon                 
  Humaidan          2004   GnRH agonist                                    IVF                               115             30.5   FSH   Puregon     150                                  116           30.8   FSH   Puregon      150       LH    Luveris                 
  Loutradis         2004   GnRH agonist                                    IVF                               106             37.3   FSH               200                                  98            38.1   FSH                200       hMG                           
  De Placido        2005   GnRH agonist                                    IVF                               58              30.4   FSH   Gonal F     225                                  57            31.5   FSH   Gonal F      225       LH    Luveris      150        
  Drakakis          2005   GnRH agonist                                    IVF                               22              33.0   FSH   Puregon     200                                  24            32.4   FSH   Puregon      200       hMG   Menogon      75         
  Filicori          2005   GnRH agonist                                    IVF                               24              33.4   FSH   Puregon     225                                  24            33.8   FSH   Puregon      225       hCG   Gonasi       200        
  Gómez-Palomares   2005   GnRH antagonist                                 IVF                               58              39.0   FSH   Gonal F     225   hMG    HMG-Lepori   75    4    36            38.8   FSH   Gonal F      300       LH    Luveris      75         2
  Griesinger        2005   GnRH antagonist                                 IVF                               65              30.5   FSH   Gonal F     150                             11   62            30.3   FSH   Gonal F      150       LH    Luveris      75         6
  Hugues            2005   None                                            IVF                               30              29.9   FSH   Gonal F     150                             0    117           29.3   FSH   Gonal F      150       LH    Luveris      150--300   1
  Fabregues         2006   GnRH agonist                                    IVF                               60              38.2   FSH   Gonal F     150                             5    60            38.4   FSH   Gonal F      150       LH    Luveris      150        5
  Levi-Setti        2006   GnRH antagonist                                 IVF                               20              32.3   FSH   Gonal F     225                             4    20            32.2   FSH   Gonal F      150       LH    Luveris      75         2
  Tarlatzis         2006   GnRH agonist                                    IVF                               59              30.3   FSH   Gonal F     150                             2    55            30.5   FSH   Gonal F      150       LH    Luveris      75         0
  Berkkanoglu       2007   GnRH agonist                                    IVF                               51              34.9   FSH   Gonal F     600                                  46            36.3   FSH   Gonal F      600       LH    Luveris      75         
  Berkkanoglu       2007   GnRH agonist                                    IVF                               51              34.9   FSH   Gonal F     600                                  48            35.2   FSH   Gonal F      600       hCG   Ovitrelle    75         
  Demirol           2007   None                                            IUI                               161             30.4   FSH   Gonal F     150                             0    80            30.8   hMG                150                                     0
  Ziebe             2007   GnRH agonist                                    IVF                               368                    FSH               225                                  363                  hMG                225                                     
  Barrenetxea       2008   GnRH agonist                                    IVF                               42              41.8   FSH   Gonal F     300                                  42            42.1   FSH   Gonal F      300       LH    Luveris      150        
  Bosch             2008   GnRH antagonist                                 IVF                               140             33.4   FSH   Gonal F     225                             20   140           33.2   hMG   Menopur      225                                     23
  Hompes            2008   GnRH antagonist                                 IVF                               317             32.0   FSH   Gonal F     150                             15   312           31.7   hMG   Menopur      150                                     19
  Nyboeandersen     2008   GnRH agonist                                    IVF                               261             31.8   FSH   Gonal F     150                             0    265           31.7   FSH   Gonal F      150       LH    Luveris      75         0
  Blockeel          2009   GnRH antagonist                                 IVF                               35              30.0   FSH   Puregon     225                             3    35            29.0   FSH   Puregon      225       hCG   Pregnyl      200        6
  Check             2009   GnRH antagonist                                 IVF                               35              35.1   FSH               300                             1    35            33.6   FSH                300       hCG                25         3
  Drakakis          2009   GnRH agonist                                    IVF                               58              36.4   FSH   Gonal F     200   rhCG                200        56            37.3   FSH   Gonal F      200       LH                            
  Matorras          2009   GnRH agonist                                    IVF                               68              36.7   FSH   Gonal F     300                             3    63            36.6   FSH   Gonal F      300       LH    Luveris      150        0
  Melo              2010   GnRH agonist                                    IVF                               346             24.9   FSH   Gonal F     225                                  333           23.9   hMG   Menopur      225                                     
  Pacchiarotti      2010   GnRH antagonist                                 IVF                               60                     hMG   Menopur     225                             2    62                   FSH   Pergoveris   225       LH    Luveris                 8
  Bosch             2011   GnRH antagonist                                 IVF                               314             34.6   FSH   Gonal F     225                             50   311           34.7   FSH   Gonal F      150       LH    Luveris      75         56
  Caserta           2011   GnRH agonist                                    IVF                               501             34.8   FSH   Gonal F     150                                  498           34.3   FSH   Gonal F      150       LH                            
  Kokac             2011   GnRH agonist                                    IUI                               24              29.5   FSH   Gonal F     75                                   25            28.8   hMG   Merional     75                                      
  Pezzuto           2011   GnRH agonist                                    IVF                               40              34.0   FSH   Puregon     225                                  40            35.0   FSH   Puregon      225       LH    Luveris      75         
  Sagnella          2011                                                   IUI                               262             35.4   FSH   Gonal F     150                             23   261           35.0   hMG   Meropur      75--150                                 5
  Barberi           2012   GnRH agonist                                    IVF                               11              32.3   FSH   Gonal F     150                             10   9             34.1   FSH   Gonal F      150       LH    Luveris      75         2
  Devroy            2012   GnRH antagonist                                 IVF                               375             30.4   FSH   Puregon     150                             59   374           30.8   hMG   Menopur      150                                     69
  Lisi              2012   GnRH agonist                                    IVF                               75              32.8   FSH   Gonal F     150                                  75            33.6   FSH   Gonal F      150       LH                 75         
  Madani            2012   GnRH antagonist                                 IVF                               26              39.2   FSH   Gonal F     300                             0    47            38.9   FSH   Gonal F      300       hCG   Pregnyl      200        0
  Revelli           2012   GnRH antagonist                                 IVF                               266             39.2   FSH   Gonal F     300                             27   264           39.4   FSH   Gonal F      150       LH    Luveris      150        29
  Thuesen           2012   GnRH agonist                                    IVF                               16              31.5   FSH   Puregon     150                             2    46            32.6   FSH   Puregon      150       hCG   Predalon     100        5
  Ye                2012   GnRH agonist                                    IVF                               64              36.2   FSH   Gonal F     225                                  63            36.2   hMG   Menopur      225                                     
  Konig             2013   GnRH antagonist                                 IVF                               128             37.9   FSH   Gonal F     225                             17   125           38.0   FSH   Gonal F      225       LH    Luveris      150        14
  Rashidi           2013                                                   IUI                               132             28.7   FSH   Gonal F     75                              3    127           29.1   hMG   Menogon      75                                      1
  Thuesen           2013   GnRH agonist                                    IVF                               16              32.3   FSH   Puregon     150                             0    46            32.3   FSH   Puregon      150       hCG   Predalon     100        0
  Razi              2014   GnRH agonist                                    IVF                               20              31.3   FSH   Gonal F     150                             0    20            31.8   FSH   Gonal F      150       LH    Luveris      75         0
  Behre             2015   GnRH agonist                                    IVF                               99              37.6   FSH   Gonal F     300                             1    103           37.4   FSH   Gonal F      300       LH    Luveris      150        2
  Moro              2015   none                                            IUI                               289             37.9   hMG   Meropur     150                             5    290           38.4   FSH   Gonal F      150       LH    Luveris      150        13
  Vuong             2015   GnRH antagonist                                 IVF                               120             38.0   FSH   Gonal F     300                             11   120           38.0   FSH   Gonal F      300       LH    Pergoveris   150        18
  Yilmaz            2015   GnRH agonist                                    IVF                               87              29.0   FSH   Puregon                                          50            30.3   FSH   Puregon                LH    Luveris      75         
  Younis            2016   GnRH antagonist                                 IVF                               30              38.6   FSH   Gonal F     300                             6    32            38.9   FSH   Gonal F      300       LH    Luveris      150        5

Although studies considered in the meta-analysis used different endpoints, we performed an overall meta-analysis considering all studies evaluating at least pregnancy rate or number of oocytes retrieved.

The investigators (DS and LC), using Cochrane risk-of-bias algorithm, independently assessed the risk-of-bias for all trials. The following quality criteria and methodological details were evaluated for each trial included in the meta-analysis: (i) method of randomization, even if the randomization was not an inclusion criterion; (ii) concealment of allocation; (iii) presence or absence of blinding to treatment allocation; (iv) duration and type of treatment and follow-up phases; (v) number of participants recruited, analyzed, or lost to follow-up; (vi) timing of trial; (vii) whether an intention to treat analysis was done; (viii) whether a power calculation was done; (ix) source of funding; and (x) criteria for including participants and assessing outcomes.

Summary Measures {#S2-4}
----------------

The primary outcome was the number of oocytes retrieved, evaluated as mean difference between the two types of treatment compared. The choice of the primary endpoint derived from the consideration that the number of oocytes retrieved is the unique endpoint available in almost all trials in ART setting. Moreover, our meta-analysis aimed at comparing the efficacy *in vivo* of gonadotropin combinations, and the number of oocytes retrieved best described pathophysiologically the first step influenced by gonadotropin administration, i.e., follicular and oocyte development. The oocytes number remains the first measurable and reproducible parameter to describe gonadotropin action *in vivo*.

In clinical practice, the main ART outcome remains live birth rate. However, this parameter was not considered as primary endpoint in our meta-analysis, since it is influenced by a large number of unquantifiable biases and variables. Indeed, the vast majority of clinical trials dedicated to ART outcome do not report this parameter. In fact, the step following oocyte collection, i.e., embryo development, is strongly influenced by another important confounding factor, i.e., sperm quality, which is usually (and unexplainably) disregarded. Further, implantation rate follows embryo development and it is, in turn, affected by other factors, such as the endometrium thickness and activity, which are usually not controlled for. Continuing until pregnancy and live birth rate, each step is influenced by a number of factors, not immediately dependent on gonadotropins. Accordingly, the relationship between live birth rate and oocytes retrieved is suggested in the literature ([@B15]), but not universally accepted ([@B16], [@B17]). For these reasons, it is not possible to identify a unique endpoint to evaluate COS outcomes. Thus, we considered each available COS outcome after the number of oocytes retrieved as secondary endpoints, i.e., MII oocytes number, embryos, implantation rate, pregnancy rate, and live birth rate. Moreover, FSH dosage used and the ratio FSH dosage/number of oocytes retrieved were evaluated in order to describe the amount of gonadotropin needed to obtain each oocyte."

Data Synthesis and Analysis {#S2-5}
---------------------------

The meta-analysis was conducted using the Review Manager (RevMan) software (Version 5.3.1 Copenhagen: The Nordic Cochrane Center, The Cochrane Collaboration, 2014). Data were combined using the fixed effect model and weighted mean differences, and 95% confidence intervals were estimated for each endpoint. The random effect model was used when high heterogeneity resulted among studies, as evaluated by *I*^2^ statistics. Meta-regression analyses were performed to evaluate the relationship between continuous variables.

Values of *p* \< 0.05 were considered statistically significant.

Risk-of-Bias across Studies {#S2-6}
---------------------------

Two authors (Santi Daniele and Casarini Livio) independently evaluated risk-of-bias. Although randomization is not a strict inclusion criterion, it was evaluated as source of biases following the suggestions provided by the Cochrane collaboration.

Results {#S3}
=======

Of the 2,117 publications initially identified, 1,602 remained after duplicates removal. According to the strategy research, we identified 196 potentially relevant studies, based on the information given in the abstract. All trials were thoroughly appraised for eligibility in the meta-analysis and methodological quality. Seventy studies were included in the final analysis (Table [2](#T2){ref-type="table"}; Figure [1](#F1){ref-type="fig"}).

![**Study flow chart**.](fendo-08-00114-g001){#F1}

Considerations on Study Design {#S3-1}
------------------------------

The mean age of all patients was 33.21 ± 3.43 years. Considering the wide heterogeneity in clinical trials included in the analysis, regarding inclusion criteria, FSH starting dose chosen and ART approaches, several subgroup analyses were performed (Table [3](#T3){ref-type="table"}). In a subgroup analyses, studies were divided according to the GnRH analog used, agonist or antagonist, respectively. In subgroup analyses, three studies were excluded considering that hMG was administered together with FSH ([@B18]--[@B20]). An insufficient number of studies were available on the comparison between FSH alone vs. FSH + hCG and between FSH + LH vs. FSH + hCG, limiting the possibility to subgroup studies. Finally, considering the whole group of studies included in the meta-analysis, the ART approaches chosen after COS were different, ranging from intrauterine insemination (IUI) to intracytoplasmatic sperm injection (ICSI). However, only four studies evaluated IUI ([@B21]--[@B24]), thus the vast majority of trials included in the analysis considered IVF/ICSI. Moreover, of these four studies, three compared hMG to FSH alone ([@B21]--[@B23]) and one LH + FSH to FSH + hCG alone ([@B24]). Thus, a subgroup analysis, excluding studies performing IUI, was performed.

###### 

**Number of studies evaluated in each comparison and in each subgroup analysis**.

                                                                FSH + LH vs. FSH alone   FSH + hCG vs. FSH alone   hMG vs. FSH alone
  ------------------------------------------------------------- ------------------------ ------------------------- -------------------
  Overall analyses                                              34                       9                         29
  **Subgroup analyses**                                                                                            
  GnRH antagonists                                              10                       3                         5
  GnRH agonists                                                 22                       6                         20
  GnRH analogs missing data                                     *2*                      *0*                       *4*
  *In vitro* fertilization/intracytoplasmatic sperm injection   33                       9                         26
  Intrauterine insemination                                     1                        0                         3
  ART schemes missing information                               *0*                      *0*                       *0*

*ART, assisted reproductive technology; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone; hCG, human chorionic gonadotropin; LH, luteinizing hormone*.

Number of Oocytes Retrieved {#S3-2}
---------------------------

Twenty-nine studies evaluated the comparison of FSH alone vs. FSH + LH, for a total of 5,840 patients. Studies using FSH alone retrieved a significantly higher number of oocytes compared to FSH + LH treatment (*p* = 0.010) (Figure [2](#F2){ref-type="fig"}A; Table [4](#T4){ref-type="table"}). However, different results were found depending on COS protocol. In particular, higher oocyte numbers were retrieved when FSH was administered alone in a GnRH agonist protocol (*p* = 0.010), while no differences were observed in GnRH antagonist protocol (*p* = 0.840) (Table [4](#T4){ref-type="table"}).

###### 

**Forrest plot evaluating the retrieved oocytes number comparing follicle-stimulating hormone alone to luteinizing hormone (A), human chorionic gonadotropin (B), and human menopausal gonadotropin (C)**.

![](fendo-08-00114-g002a)
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###### 

**Main results of meta-analyses subgroups**.

                                                  Luteinizing hormone (LH) + follicle-stimulating hormone (FSH) vs. FSH   Human chorionic gonadotropin (hCG) + FSH vs. FSH   Human menopausal gonadotropin (hMG) vs. FSH   LH + FSH vs. hCG + FSH
  ----------------------------------------------- ----------------------------------------------------------------------- -------------------------------------------------- --------------------------------------------- ------------------------
  **Oocytes retrieved (mean difference)**                                                                                                                                                                                  
  Overall analysis                                −0.20 (−0.36, −0.04)                                                    0.24 (−2.27, 2.75)                                 −0.92 (−1.45, −0.39)                          0.39 (−0.83, 1.61)
  ***p* = 0.01**                                  *p* = 0.850                                                             ***p* \< 0.001**                                   *p* = 0.530                                   
  *I*^2^ = 88%                                    *I*^2^ = 99%                                                            *I*^2^ = 94%                                       *I*^2^ = 96%                                  
                                                                                                                                                                                                                           
                                                  29 studies                                                              7 studies                                          20 studies                                    5 studies
  5,840 patients                                  948 patients                                                            5,512 patients                                     538 patients                                  
                                                                                                                                                                                                                           
  Gonadotropin-releasing hormone (GnRH) agonist   −0.35 (−0.63, −0.08)                                                    --                                                 −0.43 (−0.95, 0.10)                           --
  ***p* = 0.01**                                  *p* = 0.11                                                                                                                                                               
  *I*^2^ = 93%                                    *I*^2^ = 93%                                                                                                                                                             
                                                                                                                                                                                                                           
                                                  17 studies                                                                                                                 16 studies                                    
  3,677 patients                                  3,347 patients                                                                                                                                                           
                                                                                                                                                                                                                           
  GnRH antagonist                                 0.01 (−0.13, 0.16)                                                      --                                                 −2.38 (−3.10, −1.66)                          --
  *p* = 0.840                                     ***p* \< 0.001**                                                                                                                                                         
  *I*^2^ = 54%                                    *I*^2^ = 42%                                                                                                                                                             
                                                                                                                                                                                                                           
                                                  10 studies                                                                                                                 4 studies                                     
  2,163 patients                                  2,165 patients                                                                                                                                                           
                                                                                                                                                                                                                           
  **FSH/oocytes (mean difference)**                                                                                                                                                                                        
  Overall analysis                                −0.16 (−0.21, −0.11)                                                    −0.04 (−0.17, 0.09)                                0.17 (0.11, 0.23)                             −0.25 (−0.94, 0.44)
  ***p* \< 0.001**                                *p* = 0.550                                                             ***p* \< 0.001**                                   *p* = 0.480                                   
  *I*^2^ = 92%                                    *I*^2^ = 84%                                                            *I*^2^ = 86%                                       *I*^2^ = 90%                                  
                                                                                                                                                                                                                           
                                                  26 studies                                                              6 studies                                          15 studies                                    4 studies
  5,404 patients                                  893 patients                                                            4,436 patients                                     382 patients                                  
                                                                                                                                                                                                                           
  GnRH agonist                                    −0.06 (−0.13, 0.01)                                                     --                                                 0.07 (−0.01, 0.14)                            --
  *p* = 0.080                                     *p* = 0.090                                                                                                                                                              
  *I*^2^ = 90%                                    *I*^2^ = 84%                                                                                                                                                             
                                                                                                                                                                                                                           
                                                  18 studies                                                                                                                 12 studies                                    
  3,613 patients                                  2,900 patients                                                                                                                                                           
                                                                                                                                                                                                                           
  GnRH antagonist                                 −0.36 (−0.45, −0.26)                                                    --                                                 0.35 (0.25, 0.45)                             --
  ***p* \< 0.001**                                ***p* \< 0.001**                                                                                                                                                         
  *I*^2^ = 95%                                    *I*^2^ = 74%                                                                                                                                                             
                                                                                                                                                                                                                           
                                                  8 studies                                                                                                                  3 studies                                     
  1,791 patients                                  1,536 patients                                                                                                                                                           
                                                                                                                                                                                                                           
  **MII oocytes (mean difference)**                                                                                                                                                                                        
  Overall analysis                                −0.27 (−0.56, 0.02)                                                     −0.37 (−2.45, 1.71)                                −0.60 (−1.31, 0.12)                           −0.54 (−1.13, 0.05)
  *p* = 0.07                                      *p* = 0.730                                                             *p* = 0.10                                         *p* = 0.07                                    
  *I*^2^ = 94%                                    *I*^2^ = 91%                                                            *I*^2^ = 89%                                       *I*^2^ = 92%                                  
                                                                                                                                                                                                                           
                                                  20 studies                                                              5 studies                                          11 studies                                    4 studies
  3,544 patients                                  352 patients                                                            2,871 patients                                     424 patients                                  
                                                                                                                                                                                                                           
  GnRH agonist                                    −0.50 (−1.01, 0.01)                                                     --                                                 0.15 (−1.30, 1.60)                            --
  *p* = 0.05                                      *p* = 0.84                                                                                                                                                               
  *I*^2^ = 96%                                    *I*^2^ = 86%                                                                                                                                                             
                                                                                                                                                                                                                           
                                                  13 studies                                                                                                                 7 studies                                     
  1,915 patients                                  706 patients                                                                                                                                                             
                                                                                                                                                                                                                           
  GnRH antagonist                                 0.04 (−0.08, 0.15)                                                      --                                                 −1.36 (−1.51, −1.21)                          --
  *p* = 0.54                                      ***p* \< 0.001**                                                                                                                                                         
  *I*^2^ = 17%                                    *I*^2^ = 0%                                                                                                                                                              
                                                                                                                                                                                                                           
                                                  7 studies                                                                                                                  4 studies                                     
  1,629 patients                                  2,165 patients                                                                                                                                                           
                                                                                                                                                                                                                           
  **Embryos (mean difference)**                                                                                                                                                                                            
  Overall analysis                                −0.04 (−0.17, 0.10)                                                     0.07 (−0.39, 0.53)                                 0.19 (0.07, 0.30)                             −0.12 (−0.19, −0.06)
  *p* = 0.54                                      *p* = 0.77                                                              ***p* = 0.001**                                    ***p* \< 0.001**                              
  *I*^2^ = 83%                                    *I*^2^ = 74%                                                            *I*^2^ = 94%                                       *I*^2^ = 83%                                  
                                                                                                                                                                                                                           
                                                  26 studies                                                              7 studies                                          16 studies                                    4 studies
  4,721 patients                                  918 patients                                                            3,321 patients                                     500 patients                                  
                                                                                                                                                                                                                           
  GnRH agonist                                    −0.07 (−0.25, 0.11)                                                     --                                                 0.23 (0.10, 0.35)                             --
  *p* = 0.43                                      ***p* \< 0.001**                                                                                                                                                         
  *I*^2^ = 88%                                    *I*^2^ = 95%                                                                                                                                                             
                                                                                                                                                                                                                           
                                                  17 studies                                                                                                                 13 studies                                    
  2,890 patients                                  2,589 patients                                                                                                                                                           
                                                                                                                                                                                                                           
  GnRH antagonist                                 0.03 (−0.11, 0.18)                                                      --                                                 −0.02 (−0.19, 0.16)                           --
  *p* = 0.64                                      *p* = 0.86                                                                                                                                                               
  *I*^2^ = 36%                                    *I*^2^ = 74%                                                                                                                                                             
                                                                                                                                                                                                                           
                                                  9 studies                                                                                                                  3 studies                                     
  1,831 patients                                  732 patients                                                                                                                                                             
                                                                                                                                                                                                                           
  **Implantation rate (mean difference)**                                                                                                                                                                                  
  Overall analysis                                0.11 (0.00, 0.21)                                                       −0.06 (−0.03, 0.01)                                0.22 (0.02, 0.23)                             −0.00 (−0.16, 0.15)
                                                  *p* = 0.05                                                              *p* = 0.59                                         ***p* = 0.03**                                *p* = 0.98
                                                  *I*^2^ = 99%                                                            *I*^2^ = 0%                                        *I*^2^ = 100%                                 *I*^2^ = 96%
                                                                                                                                                                                                                           
                                                  15 studies                                                              5 studies                                          10 studies                                    4 studies
                                                  2,669 patients                                                          749 patients                                       3,208 patients                                430 patients
                                                                                                                                                                                                                           
  GnRH agonist                                    0.16 (0.00, 0.31)                                                       --                                                 0.25 (−0.01, 0.51)                            --
                                                  *p* = 0.05                                                                                                                 *p* = 0.06                                    
                                                  *I*^2^ = 100%                                                                                                              *I*^2^ = 100%                                 
                                                                                                                                                                                                                           
                                                  10 studies                                                                                                                 8 studies                                     
                                                  1,256 patients                                                                                                             2,299 patients                                
                                                                                                                                                                                                                           
  GnRH antagonist                                 0.01 (−0.08, 0.10)                                                      --                                                 0.15 (0.13, 0.17)                             --
                                                  *p* = 0.83                                                                                                                 ***p* \< 0.001**                              
                                                  *I*^2^ = 85%                                                                                                               *I*^2^ = 0%                                   
                                                                                                                                                                                                                           
                                                  6 studies                                                                                                                  2 studies                                     
                                                  1,393 patients                                                                                                             909 patients                                  
                                                                                                                                                                                                                           
  **Pregnancy rate (odds ratio)**                                                                                                                                                                                          
  Overall analysis                                1.20 (1.06, 1.37)                                                       0.96 (0.72, 1.26)                                  1.10 (0.98, 1.22)                             1.73 (1.26, 2.38)
                                                  ***p* = 0.004**                                                         *p* = 0.750                                        *p* = 0.100                                   ***p* \< 0.001**
                                                  *I*^2^ = 5%                                                             *I*^2^ = 0%                                        *I*^2^ = 0%                                   *I*^2^ = 48%
                                                                                                                                                                                                                           
                                                  29 studies                                                              8 studies                                          25 studies                                    5 studies
                                                  5,665 patients                                                          968 patients                                       6,894 patients                                989 patients
                                                                                                                                                                                                                           
  GnRH agonist                                    1.27 (1.09, 1.48)                                                       --                                                 1.17 (1.01, 1.36)                             --
                                                  ***p* = 0.002**                                                                                                            ***p* = 0.030**                               
                                                  *I*^2^ = 9%                                                                                                                *I*^2^ = 0%                                   
                                                                                                                                                                                                                           
                                                  22 studies                                                                                                                 17 studies                                    
                                                  3,834 patients                                                                                                             3,627 patients                                
                                                                                                                                                                                                                           
  GnRH antagonist                                 1.08 (0.87, 1.35)                                                       --                                                 1.10 (0.90, 1.34)                             --
                                                  *p* = 0.480                                                                                                                *p* = 0.370                                   
                                                  *I*^2^ = 0%                                                                                                                *I*^2^ = 0%                                   
                                                                                                                                                                                                                           
                                                  9 studies                                                                                                                  4 studies                                     
                                                  1,831 patients                                                                                                             2,165 patients                                
                                                                                                                                                                                                                           
  **Live birth rate (odds ratio)**                                                                                                                                                                                         
  Overall analysis                                1.29 (0.91, 1.84)                                                       --                                                 1.13 (0.95, 1.33)                             --
                                                  *p* = 0.15                                                                                                                 *p* = 0.17                                    
                                                  *I*^2^ = 45%                                                                                                               *I*^2^ = 10%                                  
                                                                                                                                                                                                                           
                                                  5 studies                                                               --                                                 7 studies                                     --
                                                  164 patients                                                                                                               747 patients                                  

*Bold character indicates significant results*.

Seven studies using FSH alone vs. FSH + hCG were compared, for a total of 948 patients. The overall analysis did not find significant differences in the number of oocytes retrieved between groups (*p* = 0.850) (Figure [2](#F2){ref-type="fig"}B; Table [4](#T4){ref-type="table"}).

Twenty studies compared hMG with FSH for COS, for a total of 5,512 patients. Number of oocytes retrieved was significantly higher in FSH than hMG group (*p* \< 0.001) (Figure [2](#F2){ref-type="fig"}C; Table [4](#T4){ref-type="table"}). Four of these studies used a GnRH antagonist protocol, confirming the significant increase of oocytes retrieved (*p* \< 0.001), but no difference was found in the 16 studies using GnRH agonist protocol (*p* = 0.110) (Table [4](#T4){ref-type="table"}).

Finally, 5 studies evaluated the oocytes number comparing FSH plus LH to FSH plus hCG, for a total of 538 women. The analysis did not find significant difference between groups (*p* = 0.530) (Table [4](#T4){ref-type="table"}).

FSH Dose/Retrieved Oocyte Ratio {#S3-3}
-------------------------------

The FSH/retrieved oocyte ratio was significantly lower when LH was added to FSH (*p* \< 0.001) (Table [4](#T4){ref-type="table"}), as evaluated in 26 studies for a total of 5,404 women enrolled. However, different results were found considering the protocol of COS used. In particular, no significant difference was observed in GnRH agonist protocol (*p* = 0.080) (Table [4](#T4){ref-type="table"}). On the contrary, a lower ratio was obtained when LH was added to FSH in the GnRH antagonist protocol (*p* \< 0.001) (Table [4](#T4){ref-type="table"}).

On the other hand, 6 studies compared the use of FSH alone with FSH plus hCG, for a total of 893 patients. The overall analysis did not find significant differences in the ratio between FSH dose and oocytes retrieved between groups (*p* = 0.550) (Table [4](#T4){ref-type="table"}).

Fifteen studies compared hMG with FSH for COS, for a total of 4,436 patients. The ratio between FSH dose and the number of oocytes retrieved was significantly lower in the FSH compared to hMG group (*p* \< 0.001) (Table [4](#T4){ref-type="table"}). This significant difference was lost in the 12 studies using a GnRH agonist protocol (*p* = 0.090), while remained in the three studies using a GnRH antagonist protocol (*p* \< 0.001) (Table [4](#T4){ref-type="table"}).

Finally, 4 studies evaluated the ratio comparing FSH plus LH to FSH plus hCG, for a total of 382 women. No differences in the FSH/retrieved oocyte ratio were found between groups (*p* = 0.480) (Table [4](#T4){ref-type="table"}).

MII Oocytes {#S3-4}
-----------

Twenty studies reported the MII oocytes number, comparing FSH alone and FSH + LH. The two groups did not differ considering the mean MII oocytes number (*p* = 0.050), even when GnRH agonist or antagonist protocols were considered separately (*p* = 0.050 and *p* = 0.540, respectively) (Table [4](#T4){ref-type="table"}).

Five studies compared FSH alone vs. FSH + hCG, without finding differences in the mean MII oocytes number (*p* = 0.730) (Table [4](#T4){ref-type="table"}).

Eleven studies compared FSH vs. hMG, finding no differences in the mean difference of MII oocytes (*p* = 0.100) (Table [4](#T4){ref-type="table"}). Although this result remained also considering GnRH agonist protocols (*p* = 0.840), the MII oocytes number was significantly higher when FSH was used rather than hMG (*p* \< 0.001) (Table [4](#T4){ref-type="table"}).

Four studies compared directly FSH + LH vs. FSH + hMG, finding no difference in the MII oocytes number (*p* = 0.070) (Table [4](#T4){ref-type="table"}).

Embryos {#S3-5}
-------

Twenty-six studies reported the embryo number in the comparison between FSH alone vs. FSH + LH, without significant differences (*p* = 0.540) (Table [4](#T4){ref-type="table"}). Similarly, no differences were observed in the GnRH agonist (*p* = 0.430) and antagonist group (*p* = 0.640).

Seven studies demonstrated a similar embryo number in the comparison of FSH alone vs. FSH + hCG (*p* = 0.770) (Table [4](#T4){ref-type="table"}).

Sixteen studies described the embryo number in the comparison between FSH and hMG. In this subgroup, hMG showed a higher embryo number (*p* = 0.001), maintained when GnRH agonist was used (*p* \< 0.001), but not in the GnRH antagonist group (*p* = 0.860) (Table [4](#T4){ref-type="table"}).

The direct comparison between FSH + LH and FSH + hMG demonstrated a higher embryo number when FSH was used combined to LH (*p* \< 0.001) (Table [4](#T4){ref-type="table"}).

Implantation Rate {#S3-6}
-----------------

The implantation rate was calculated as the ratio between number of gestational sacs and the number of transferred embryos. This was reported in 15 studies comparing FSH alone vs. FSH + LH, demonstrating a similar rate (*p* = 0.050), maintained both in GnRH agonist (*p* = 0.050) and antagonist protocols (*p* = 0.830) (Table [4](#T4){ref-type="table"}).

Five studies demonstrated an equal implantation rate in the comparison FSH alone vs. FSH + hCG (*p* = 0.590) (Table [4](#T4){ref-type="table"}).

Ten studies showed a higher implantation rate when hMG was used instead of FSH (*p* = 0.030) (Table [4](#T4){ref-type="table"}). This result remained in the GnRH antagonist group (*p* \< 0.001), but not in the GnRH agonist group (*p* = 0.060) (Table [4](#T4){ref-type="table"}).

No different implantation rate was found when FSH + LH was directly compared to FSH + hMG (*p* = 0.980) (Table [4](#T4){ref-type="table"}).

Pregnancy Rate {#S3-7}
--------------

The pregnancy rate was significantly higher when LH was added to FSH (*p* = 0.004), as evaluated in 29 studies for a total of 5,565 women enrolled (Figure [3](#F3){ref-type="fig"}A; Table [4](#T4){ref-type="table"}).

###### 

**Forrest plot evaluating the pregnancy rate comparing follicle-stimulating hormone alone to luteinizing hormone (A), human chorionic gonadotropin (B), and human menopausal gonadotropin (C)**.
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Similarly, the higher pregnancy rate for the FSH plus LH group was maintained only when a GnRH agonist was used (*p* = 0.002), not with GnRH antagonist (*p* = 0.480) (Table [4](#T4){ref-type="table"}).

Eight studies compared the use of FSH alone vs. FSH + hCG, for a total of 968 patients. The overall analysis did not find significant differences in pregnancy rate between groups (*p* = 0.750) (Figure [3](#F3){ref-type="fig"}B; Table [4](#T4){ref-type="table"}).

Twenty-five studies compared hMG vs. FSH during COS, for a total of 6,894 patients. Pregnancy rate did not differ between groups (*p* = 0.100) (Figure [3](#F3){ref-type="fig"}C; Table [4](#T4){ref-type="table"}). However, pregnancy rate was significantly higher when hMG was used in a GnRH agonist protocol (*p* = 0.030), while it did not change in a GnRH antagonist regimen (*p* = 0.370) (Table [4](#T4){ref-type="table"}). In the comparison between hMG vs. FSH alone, considering only IVF/ICSI cycles, 22 studies remained in the analysis, for a total of 6,354 patients. Pregnancy rate did not differ between groups (*p* = 0.070) (Figure [S1](#SM3){ref-type="supplementary-material"} in Supplementary Material). Considering only GnRH agonist protocols, 18 studies remained in the analysis, confirming the improved pregnancy rate in hMG group vs. FSH alone (*p* = 0.003) (Figure [S2](#SM4){ref-type="supplementary-material"} in Supplementary Material).

Finally, five studies evaluated pregnancy rate comparing FSH + LH vs. FSH + hCG, for a total of 989 women. A higher pregnancy rate was observed when LH was added to FSH, rather than hCG (*p* \< 0.001) (Table [4](#T4){ref-type="table"}).

Live Birth Rate {#S3-8}
---------------

Five studies reported the live birth rate in the comparison of FSH alone vs. FSH + LH, without significant differences (*p* = 0.150) (Table [4](#T4){ref-type="table"}). Similar result was obtained when FSH alone was compared to FSH + hCG (8 studies, *p* = 0.750) and to hMG (7 studies, *p* = 0.170) (Table [4](#T4){ref-type="table"}).

Meta-Regression Analyses {#S3-9}
------------------------

Considering each subgroup analysis, the number of oocytes retrieved was directly related to the cumulative FSH dose when FSH alone was used (*R* = 0.342, *p* = 0.002), instead of the combination FSH + LH (*R* = 0.146, *p* = 0.060). On the contrary, the cumulative FSH dose was not related to the oocytes number when FSH was compared to hMG (*R* = 0.022, *p* = 0.543).

Risk-of-Bias {#S3-10}
------------

The risk-of-bias was evaluated and summarized in Figure [4](#F4){ref-type="fig"}.

![**Risk-of-bias graph: the authors' judgment about each risk-of-bias item is presented as percentages across all included studies**.](fendo-08-00114-g004){#F4}

Overall Model {#S3-11}
-------------

The main concepts found by our data analysis were graphically summarized by a plot (Figure [5](#F5){ref-type="fig"}), representing the means and 95% confidence intervals of each fertilization step and gonadotropin regimen as extensively detailed in the subchapters above. In this overall model, COS served as an example of gonadotropins efficacy *in vivo* illustrating LH and hCG action on the ovary (Figure [5](#F5){ref-type="fig"}). Second-order polynomial functions were used as a fitting model of the standard mean differences (on the Y axis) calculated for each endpoint of the meta-analysis, considering FSH + LH vs. FSH alone, FSH + hCG vs. FSH alone and hMG vs. FSH (Figure [5](#F5){ref-type="fig"}). The number of oocytes retrieved is higher when FSH is used alone in all comparison, but the addition of LH or LH activity (such as in the case of hMG) progressively improves the ART outcomes, suggesting a positive effect of LH on oocyte quality. Especially, MII oocytes, embryos, implantation rate, and pregnancy rate improve progressively and linearly when LH is used (red line), an effect attenuated when hMG is used (blue line) (Figure [5](#F5){ref-type="fig"}). On the contrary, hCG addition does not improve ART outcome (black line) (Figure [5](#F5){ref-type="fig"}).

![**Overall model of meta-analysis results**. Each scatter plot represents the mean differences with related confidence interval (95%) for each of assisted reproductive technology outcomes evaluated. The three lines represent the polynomial trend line. Red line shows the results with luteinizing hormone supplementation, blue line with human menopausal gonadotropin and black line with human chorionic gonadotropin.](fendo-08-00114-g005){#F5}

Discussion {#S4}
==========

This is the first meta-analysis comparing comprehensively the efficacy of the mostly used gonadotropin combinations in ART. We find that the administration of FSH alone during COS retrieves higher oocyte number than either LH supplementation or hMG use. However, the combined use of FSH + LH reduces the FSH dose required for oocyte retrieved, while hMG leads to higher FSH dose needed. Interestingly, FSH + LH increases the pregnancy rate of about 1.20 fold, in spite of lower number of oocyte retrieved compared to FSH alone, whereas hMG does not. On the contrary, FSH + hCG treatment does neither change final oocytes number, nor FSH dose required for each oocyte, nor pregnancy rate. Although live birth rate is usually considered a better endpoint than pregnancy rate to evaluate ART outcome, it is not reported in many studies included and our meta-analysis does not show significant difference in live birth rate. All these differences are modest but, although apparently not clinically relevant, they are useful to better understand *in vivo* the overall effects of the different gonadotropin regimens.

These results suggest that gonadotropin preparations differently influence COS outcome, providing some evidence for ART personalization and improvement and leading to different results compared to those of previous meta-analyses. This difference could be due to the wide range of studies evaluated, which are focused on different endpoints and patient characteristics. FSH + LH treatment is linked to a relatively lower number of oocytes retrieved but higher pregnancy rate. The addition of LH or LH-activity might increase the selective pressure exerted on follicular selection exerted by the two gonadotropins together, compensated by improved oocyte quality. Indeed, the differences between FSH alone and FSH + LH or LH activity are lost, at least in terms of MII oocyte number. Moreover, the use of hMG leads to a higher embryos number and implantation rate compared to FSH alone. These results confirmed that the higher pregnancy rate found when FSH + LH or hMG are used together with GnRH agonist protocol, instead of FSH alone, is due to a positive effect of better oocyte quality on fertilization and embryo implantation. On the contrary, FSH + hCG treatment does not change ART outcomes compared to FSH alone, suggesting that LH and hCG result in different actions *in vivo* in the presence of FSH, reflecting *in vitro* observations ([@B3]). The overall model (Figure [5](#F5){ref-type="fig"}) shows a progressively better outcome when FSH is used together with LH or LH-activity (such as hMG). Thus, LH and hCG action *in vivo* is different in women undergoing COS, with LH improving oocyte maturation and quality, and therefore pregnancy rate, more than hCG, reflecting previous *in vitro* data.

Luteinizing hormone and hCG are characterized by specific molecular and biochemical features; they interact with distinct binding sites of the same receptor ([@B25]--[@B27]), resulting in lower dissociation rate by hCG than LH binding ([@B28]). Gonadotropin-specific ligand-receptor features imply different gene expression and intracellular signaling *in vitro*, whereby LH triggers higher levels of ERK1/2- and AKT-pathway activation than hCG, which, in turn, mediates more potent cAMP increase in human primary granulosa cells ([@B2]). Downstream effects of gonadotropins' signaling consist in LH-related proliferative and anti-apoptotic signals, vs. high steroidogenic potential and pro-apoptotic activity of hCG *in vitro*, in both human and goat primary granulosa cells ([@B3], [@B29]). In particular, cell death was described as a result of the intracellular cross-talk among cAMP/protein kinase A (PKA)-mediated steroidogenic and pro-apoptotic pathways ([@B30]) preferentially activated by FSH and hCG, in steroidogenic cells *in vitro* ([@B31]).

Interestingly, our analysis of the literature reveals that LH addition to FSH treatment for ART provides lower oocyte numbers than other treatments, probably as a result of higher follicular selection (which is apoptosis-mediated). In this regard, few speculative considerations should be done. First, COS cycles are far from being a physiologic hormonal regimen; they are optimized for multi-follicular maturation in order to obtain the highest number of healthy oocytes ([@B32]), subjecting ovaries to treatments with pre-designed, high doses of exogenous hormones, which change the natural endocrine *milieu* of the woman. As a result, a mono-ovulatory species becomes multi-ovulatory, deviating from the natural, cyclic balance between gonadotropins and steroid hormones ([@B33]) and, thereby, life/death signals, a situation clearly different from ovarian physiology. On the other hand, FSH and LH are naturally produced to regulate mono-follicular selection, growth and maturation. The message provided by *in vitro* studies is that highly steroidogenic gonadotropins, i.e., FSH and hCG, mediate apoptotic stimuli in granulosa cells *via* cAMP/PKA-pathway ([@B2], [@B3], [@B29]--[@B31]). In the ovarian setting of a multi-follicular maturation as in COS, stimulation is a potent signal for early tertiary follicle recruitment ([@B34]) and triggering steroidogenesis, results in estrogen over-production which, in turn, induces more pronounced multi-follicular survival and maturation ([@B35]) than that inducible by LH treatment.

The ART outcome obtained with hMG reflects the heterogeneity typical of this compound. hMG derives from post-menopausal or pregnant women and contains both FSH and LH activities ([@B36]). LH activity is provided by residual LH molecules and by hCG supplementation, leading to high variability of the product ([@B37]). Moreover, given the high steroidogenic potential of hCG demonstrated *in vitro* ([@B2], [@B31]), which is more similar to that of FSH rather than LH ([@B31]), it is not surprising that ART outcome does not change whether hMG is used instead of FSH, except in GnRH agonist protocols, where high oocyte numbers might possibly occur as a positive effect of the flare-up phase on follicle recruitment. The discrepancy provided by GnRH-agonist and -antagonist protocols was not demonstrated by previous meta-analyses, likely due to strict inclusion criteria focused specifically on the evaluation of the analog instead of gonadotropins combination. The most recent meta-analysis on this field suggests only a significant adverse events occurrence reduction when GnRH antagonists are used ([@B38]).

This study suggests that GnRH antagonist protocol may be disadvantageous for oocytes quality, although the addition of LH seems to compensate, at least in part, this negative effect. FSH alone allows higher number of oocytes retrieved than FSH + LH, in GnRH agonist, but not antagonist protocols. GnRH antagonist is linked to lower FSH doses required for each oocyte retrieved, in the presence of LH. Moreover, pregnancy rate is higher by hMG than FSH treatment in GnRH agonist, but not antagonist protocols. This reflects the different mechanism of action and possibly different effects among GnRH analogs, which was hypothesized, although largely debated ([@B39]). GnRH analogs are differently used in clinical practice. In particular, GnRH agonists are generally proposed in women with BMI \<25 kg/m^2^ ([@B40]), in poor responders ([@B38], [@B41]), and/or as a final trigger to minimize the ovarian hyperstimulation syndrome (OHSS) occurrence ([@B42]). Overall, GnRH antagonist is linked to reduced COS duration and overall medical costs of the stimulation phase and is recommended when a mild stimulation is required, such as for hyper-responder women ([@B38], [@B43]) or PCOS patients ([@B44]). These results support the hypothetical difference between agonists and antagonists, which was never demonstrated by previous meta-analyses (Table [1](#T1){ref-type="table"}).

With this in mind, the cost-effectiveness evaluation currently remains the main variable useful to guide the clinician choice in the setting of the personalized therapy ([@B45]). However, the assessment of ART costs is particularly challenging, and the consideration of both COS-related and pregnancy/infant-associated medical costs is mandatory. Several studies evaluated the ART medical costs alone, considering the cumulative gonadotropin dosages used, the cycle cancelation rate and the risk of adverse events. The FASTT study suggested that IUI was the cheapest/efficient first-line treatment ([@B46]), while the FORT-T trial suggested better cost-effectiveness results when sequential traditional embryo transfer is selected ([@B47]). Crawford et al. ([@B48]) recently evaluated the overall ART costs in 14,398 cycles, suggesting that sequential embryo transfer is more expensive, concerning the procedure costs, but markedly cheaper overall, reducing multiple live births and total, final expenses. Although each study seems to be conclusive, these results remain challenging, and international or national consensus on the best COS approach is not reached so far. Moreover, the gonadotropin combination is not generally considered in this cost-effectiveness evaluation, limiting the strength of these suggestions. Our results suggest a reduced FSH dose needed for each oocyte retrieved when the combination of FSH + LH was used for COS. Thus, the gonadotropin combination should be considered in the cost-saving evaluation of a specific ART procedure. The overall charge, even when LH, hCG, or hMG are used in addition/substitution to FSH, must be considered according to the local reimbursement system. Finally, no study so far evaluated the "weight" of gonadotropin-producing companies on the clinician's decision.

The main limit of this meta-analysis is the heterogeneity of studies included as suggested by the elevated I^2^ score. Couple infertility represents a challenging clinical condition, difficult to define according to strict clinical criteria. Indeed, different inclusion and exclusion criteria are used in each trial, making the comprehensive comparison of these results difficult. As a confirmation, a recent phase III single-blind, randomized, parallel-group clinical trial performed on 939 poor responder women did not find any safety and efficacy differences between FSH alone and FSH + LH ([@B49]). This reinforces the knowledge of a high heterogeneity of studies in ART setting, in which also the women classification as poor responders could mask the different gonadotropin effects *in vivo*. The relative high risk-of-bias of the studies included, as shown in Figure [4](#F4){ref-type="fig"}, represents an important limit that should be carefully considered to design further appropriate studies. However, although the pharmacological approach to ART is evaluated, no publication biases are evident at funnel plots analyses (data not shown). As highlighted by previous meta-analyses, we found high selection and allocation biases, confirming the finding that more than 80% of clinical trials did not apply any blinding technique ([@B50]). This high percentage is probably due to the difficulty in applying these procedures to ART, in which over 30 therapeutic complex approaches are currently available.

In conclusion, we found that different performance in ART is depending on gonadotropin combination used for COS, reflecting the physiological role of these molecules as previously indicated by *in vitro* data. This leads to important implication for clinical practice, where pregnancy rate or oocyte numbers might be the preferentially selected outcome. Especially, LH addition to FSH decreases FSH need and progressively improves ART outcomes and pregnancy rate. In GnRH agonist protocols, a better pregnancy rate is obtained by FSH + LH and hMG treatment. FSH + hCG or hMG alone are equally effective compared to FSH alone on pregnancy rate.
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